Shares of Zimmer Biomet plunged in mid-day trading, sliding 7.7% after the orthopedic-device maker disclosed an agreement to acquire the iovera° cryoneurolysis system from Pacira BioSciences for as much as $140 million. The transaction structure calls for a $70 million upfront payment plus up to $70 million in additional payments tied to revenue milestones through the end of 2031.
The iovera° device is FDA-cleared and operates without drugs, using focused cold therapy to temporarily interrupt nerve pain signals. Under the terms of the announcement, Zimmer Biomet will assume full global rights for the development, manufacture, and commercialization of the technology.
Investor attention quickly turned to the financing and balance sheet implications of adding another asset. Zimmer Biomet entered 2026 carrying roughly $6.9 billion in net debt, a level reached after integrating Paragon 28 and Monogram Technologies. The company also completed $2.75 billion in new unsecured revolving credit facilities immediately prior to today’s announcement.
Analysts have maintained a cautious stance toward the stock. Multiple firms, among them Truist and JPMorgan, have recently reduced their price targets, citing execution risks and the pace at which debt has accumulated. Those concerns are amplified by Zimmer Biomet’s modest organic revenue expansion, estimated at about 2.9%.
The wider market provided little offset. The S&P 500 was up 0.7% and the Nasdaq was up 1.3% during the same trading session, leaving Zimmer Biomet well behind the broader indices. The stock opened at $89.29, below the prior close of $91.24 after the iovera° deal was announced before the bell. Selling intensified through mid-day, driving the share price toward a session low of $84.02, which sits uncomfortably near the 52-week low of $79.12.
Taken together, the trading action signaled investor skepticism about another acquisition at a time when market participants are prioritizing stronger organic performance and tighter balance sheet discipline. While the iovera° system could strengthen Zimmer Biomet’s pain-management offerings, the immediate integration workload and cost appear to outweigh perceived strategic benefits for investors in the short term.
Summary
Zimmer Biomet announced it will buy Pacira BioSciences’ iovera° cryoneurolysis system for up to $140 million, prompting a 7.7% mid-day drop in the stock as investors weighed the deal’s balance sheet impact. The company entered 2026 with around $6.9 billion in net debt and had just finalized $2.75 billion in unsecured revolving credit facilities. Analysts have recently trimmed price targets amid execution concerns and roughly 2.9% organic revenue growth.
Key points
- Acquisition terms: $70 million upfront plus up to $70 million in revenue-based milestones through end of 2031 - Sector impact: healthcare and medical devices.
- Balance sheet focus: roughly $6.9 billion net debt entering 2026 and $2.75 billion in new unsecured revolver capacity finalized before the announcement - Sector impact: financial markets and corporate credit.
- Analyst stance: recent price-target cuts by multiple firms citing execution risk and debt pace amid modest organic growth of about 2.9% - Sector impact: equities and investor sentiment in medtech stocks.
Risks and uncertainties
- Debt accumulation: Additional acquisition payments add to leverage concerns for Zimmer Biomet, affecting investor appetite for the stock - Markets impacted: credit and equity markets.
- Execution risks: Analysts cite the challenge of integrating recent and new acquisitions, which could weigh on near-term performance - Markets impacted: healthcare equipment investors.
- Limited near-term offset: Despite potential product expansion with iovera°, near-term cost and integration burdens appear to outweigh strategic benefits for the market - Markets impacted: medical-device sector and shareholders.
The market’s reaction to the iovera° acquisition underscores heightened investor scrutiny of acquisition-led growth strategies when debt levels are already elevated and organic growth is modest. For now, the stock’s underperformance relative to the broader indices reflects that skepticism.